The combination of activin type IIA decoy receptor and intermittent parathyroid hormone reverses bone loss in mice with non-use osteopenia (2023)

Brent, MB., Lodberg, A., Bromer, FD., van der Eerden, B., Eijken, M., van den Bruel, A., & Thomsen, JS. (2021).The combination of activin type IIA decoy receptor and intermittent parathyroid hormone reverses bone loss in mice with non-use osteopenia.Bone,142, [115692].https://doi.org/10.1016/j.bone.2020.115692

Brent, MB ; Lodberg, A.; Bromer, FDet al. /The combination of activin type IIA decoy receptor and intermittent parathyroid hormone reverses bone loss in mice with non-use osteopenia. In:Bone. 2021 ; Vol. 142.

@article{2fbb98acb4be4328b4e0f21e58f7d442,

title = "Activin Type IIA decoy receptor and intermittent parathyroid hormone combine to reverse bone loss in mice with osteopenia",

abstract = "Damage to the cell bodies of the lower motor neurons or their axons results in reduced or abolished voluntary movement, accompanied by significant loss of bone and muscle mass. Intermittent parathyroid hormone 1–34 (PTH) (teriparatide) is one of the most potent bone anabolics Treatment regimens.ActRIIA-mFc is an activin type IIA decoy receptor that increases bone mass mediated by inhibition of activin receptor signaling.We examined whether PTH or ActRIIA-mFc alone or in combination reduced bone loss - and muscle mass induced by injection of botulinum toxin A (BTX) into the right hind limb of mice Seventy-two 16-week-old female C57BL/6 mice were assigned to the following groups: baseline, control, BTX, BTX + ActRIIA-mFc (10 mg /kg), BTX + PTH (100 μg/kg) and BTX + ActRIIA-mFc + PTH. Mice were sacrificed after three weeks of non-use and treatment. In contrast to PTH monotherapy, ActRIIA-mFc alone or in combination with PTH was able to partially or completely prevent the loss of total femoral bone mass, trabecular thickness and bone strength caused by disuse. In addition, an additive effect of ActRIIA-mFc and PTH on areal bone mineral density and trabecular bone volume was found. In conclusion, ActRIIA-mFc and PTH in combination were more effective in preventing disuse-induced bone loss and deterioration in trabecular microarchitecture than either treatment alone.”

author = "MB Brent and A Lodberg and FD Bromer and {van der Eerden}, Bram and M Eijken and {van den Bruel}, A and JS Thomsen",

year="2021",

doi = "10.1016/j.bone.2020.115692",

language="English",

volume = "142",

magazine = "bones",

issn = "8756-3282",

Publisher = "Elsevier Inc.",

}

Brent, MB, Lodberg, A, Bromer, FD, van der Eerden, B, Eijken, M., van den Bruel, A. & Thomsen, JS 2021, 'The combination of activin type IIA decoy receptor and intermittent parathyroid hormone reverses bone loss in mice with non-use osteopenia',Bone, Bd. 142, 115692.https://doi.org/10.1016/j.bone.2020.115692

The combination of activin type IIA decoy receptor and intermittent parathyroid hormone reverses bone loss in mice with non-use osteopenia./Brent, MB; Lodberg, A.; Bromer, FDet al.

In:Bone, Bd. 142, 115692, 2021.

research result:contribution to the journal›Article›Academic›Peer-Review

YOU - TAG

T1 - Activin type IIA decoy receptor and intermittent parathyroid hormone in combination reverses bone loss in mice with disuse osteopenia

AU-Brent, MB

AU - Lodberg, A

AU - Bromer, FD

AU - van der Eerden, Bram

AU - Eijken, M

AU - van den Bruel, A

AU - Thomsen, JS

PJ - 2021

Y1 - 2021

N2 - Damage to the cell bodies of lower motor neurons or their axons results in reduced or abolished voluntary movement, accompanied by significant loss of bone and muscle mass. Intermittent parathyroid hormone 1-34 (PTH) (teriparatide) is one of the most potent bone anabolic regimens. ActRIIA-mFc is an activin type IIA decoy receptor that increases bone mass mediated by inhibition of activin receptor signaling. We investigated whether PTH or ActRIIA-mFc alone or in combination could prevent the loss of bone and muscle mass induced by botulinum toxin A (BTX) injection into the right hind limb in mice. Seventy-two 16-week-old female C57BL/6 mice were assigned to the following groups: baseline, control, BTX, BTX + ActRIIA-mFc (10 mg/kg), BTX + PTH (100 µg/kg), and BTX + ActRIIA-mFc + PTH. Mice were sacrificed after three weeks of non-use and treatment. In contrast to PTH monotherapy, ActRIIA-mFc alone or in combination with PTH was able to partially or completely prevent disuse-induced loss of total femoral bone mass, trabecular thickness and bone strength. In addition, an additive effect of ActRIIA-mFc and PTH on areal bone mineral density and trabecular bone volume was found. In conclusion, ActRIIA-mFc and PTH in combination was more effective in preventing disuse-induced bone loss and deterioration in trabecular microarchitecture than either treatment alone.

AB - Damage to the cell bodies of lower motor neurons or their axons results in reduced or abolished voluntary movement, accompanied by significant loss of bone and muscle mass. Intermittent parathyroid hormone 1-34 (PTH) (teriparatide) is one of the most potent bone anabolic regimens. ActRIIA-mFc is an activin type IIA decoy receptor that increases bone mass mediated by inhibition of activin receptor signaling. We investigated whether PTH or ActRIIA-mFc alone or in combination could prevent the loss of bone and muscle mass induced by botulinum toxin A (BTX) injection into the right hind limb in mice. Seventy-two 16-week-old female C57BL/6 mice were assigned to the following groups: baseline, control, BTX, BTX + ActRIIA-mFc (10 mg/kg), BTX + PTH (100 µg/kg), and BTX + ActRIIA-mFc + PTH. Mice were sacrificed after three weeks of non-use and treatment. In contrast to PTH monotherapy, ActRIIA-mFc alone or in combination with PTH was able to partially or completely prevent disuse-induced loss of total femoral bone mass, trabecular thickness and bone strength. In addition, an additive effect of ActRIIA-mFc and PTH on areal bone mineral density and trabecular bone volume was found. In conclusion, ActRIIA-mFc and PTH in combination was more effective in preventing disuse-induced bone loss and deterioration in trabecular microarchitecture than either treatment alone.

U2 - 10.1016/j.bone.2020.115692

DO - 10.1016/j.bone.2020.115692

M3 - artillery

SN-8756-3282

VL-142

JO - Bones

JF - Bone

M1 - 115692

IS -

Brent MB, Lodberg A, Bromer FD, van der Eerden B, Eijken M., van den Bruel A. et al.The combination of activin type IIA decoy receptor and intermittent parathyroid hormone reverses bone loss in mice with non-use osteopenia.Bone. 2021;142:115692. doi: 10.1016/j.bone.2020.115692